Financials in USD. Standardized financial statements.
A compact view of how Caris Life Sciences, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $812.03M | $412.26M | $306.13M | $258.49M | $294.01M | $416.54M | $432.10M | $348.39M | $294.35M | $249.67M |
| Revenue Growth? | +97.0% | +34.7% | +18.4% | -12.1% | -29.4% | -3.6% | +24.0% | +18.4% | +17.9% | 0.0% |
| Cost of Revenue? | $272.87M | $233.48M | $216.82M | $178.46M | $109.86M | $216.03M | $218.47M | $179.11M | $156.86M | $123.76M |
| Gross Profit? | $539.17M | $178.78M | $89.31M | $80.02M | $184.16M | $200.51M | $213.63M | $169.29M | $137.50M | $125.91M |
| Gross Margin? | +66.4% | +43.4% | +29.2% | +31.0% | +62.6% | +48.1% | +49.4% | +48.6% | +46.7% | +50.4% |
| Operating Expenses? | $494.06M | $435.90M | $408.86M | $395.78M | $45.07M | $70.23M | $64.85M | $63.62M | $71.54M | $57.81M |
| Operating Income? | $45.11M | -$257.12M | -$319.55M | -$315.76M | $139.09M | $130.28M | $148.78M | $105.67M | $65.96M | $68.09M |
| EBITDA? | $11.38M | -$182.95M | -$260.80M | -$245.89M | $254.46M | $248.30M | $283.31M | $223.51M | $159.27M | $181.36M |
| Income Before Tax | -$68.09M | -$281.89M | -$341.42M | -$320.83M | $29.53M | $55.21M | $81.48M | $57.20M | $9.88M | $31.22M |
| Income Tax Expense | $469.87M | $0 | $0 | $0 | $1.80M | $4.19M | $2.89M | -$14.86M | $3.84M | $4.25M |
| Net Income? | -$537.96M | -$281.89M | -$341.42M | -$320.83M | $27.73M | $31.01M | $78.60M | $72.06M | $6.00M | $26.84M |
| EPS? | $-1.90 | $-2.70 | $-1.82 | $-1.57 | $1.55 | $1.72 | $3.97 | $3.74 | $0.31 | $1.29 |
| Diluted EPS? | $-1.90 | $-2.70 | $-1.82 | $-1.57 | $1.55 | $1.72 | $3.97 | $3.68 | $0.31 | $1.28 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality